TrialSignal
Clinical trial intelligence report
Novel Therapies for Resistant Focal Segmental Glomerulosclerosis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00814255-Jul 28, 2026
NCT ID
NCT00814255
Status
COMPLETED
Phase
PHASE2
Sponsor
NYU Langone Health
Executive brief
Investment-Ready Snapshot
Novel Therapies for Resistant Focal Segmental Glomerulosclerosis is a PHASE2 clinical asset sponsored by NYU Langone Health in Focal Segmental Glomerulosclerosis. SEO and diligence focus: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00814255
Indication
Focal Segmental Glomerulosclerosis
Modality
small molecule
Target
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Intervention
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.